Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years

BACKGROUND: Few data exist concerning conversion to secondary progressive MS in patients treated with disease-modifying therapies. OBJECTIVE: Determine the proportion of alemtuzumab-treated patients converting from relapsing-remitting to secondary progressive MS during the CARE-MS core and extension...

Descripción completa

Detalles Bibliográficos
Autores principales: Horáková, Dana, Boster, Aaron, Bertolotto, Antonio, Freedman, Mark S, Firmino*, Isabel, Cavalier, Steven J, Jacobs*, Alan K, Thangavelu*, Karthinathan, Daizadeh, Nadia, Poole*, Elizabeth M, Baker, Darren P, Margolin*, David H, Ziemssen, Tjalf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750777/
https://www.ncbi.nlm.nih.gov/pubmed/33414927
http://dx.doi.org/10.1177/2055217320972137

Ejemplares similares

Ejemplares similares